FMT May Boost Immunotherapy Effectiveness

AUGUST 25, 2025

FDA Approves Papzimeos for Adults With Recurrent Respiratory Papillomatosis

AUGUST 22, 2025

Texas Declares End of State Measles Outbreak

AUGUST 20, 2025

Email This Article

POSTED: DECEMBER 2, 2019

ViiV Enters Exclusive Licensing Agreement With NIH for Long-Term HIV Treatment

Broadly neutralizing antibodies can recognize and block the entry of different strains of HIV into healthy cells.
A link to this article will be included in this email.

Recipient's Email Address:

Enter email addresses separated by commas if sending to more than one person. (200 characters max)

Your Name:

Your Email Address:

Send me a copy

Personal Message: (Optional)

These email addresses will only be used to send out this message.

Please wait..

Industry News

DECEMBER 2, 2019

ViiV Enters Exclusive Licensing Agreement With NIH for Long-Term HIV Treatment

By IDSE News Staff

Related Content

FDA Changes Label for DTG-Based ART

“As there is limited understanding of reported types of neural

To read the full story, Log in or Sign up for a Free Account

Check out our new Clinical tab!

We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!

The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select